News

The National Foundation for Infectious Diseases (NFID) medical director weighs in on this year’s respiratory virus season and offers some strategies to prevent transmission.

New challenges in the fight against gonorrhea in the US.

This week a new vaccine for HIV is under development, a COVID-19 vaccine receives WHO emergency approval, and several local US health departments receive funding to combat antimicrobial resistance.

UCLA-led study examines outcomes in infants born to mothers exposed to SARS-CoV-2 during pregnancy.

With the addition of live biotherapeutic products, a provider offers some insights into delivery and treatment considerations.

The CDC stresses the importance of hepatitis B virus (HBV) vaccination, but challenges in treatment accessibility persist.

A small study offers some more information as to potential biomarkers for the ailment and may provide a better understanding of its path to potential treatments.

Early administration of simnotrelvir plus ritonavir shortened the time to sustained resolution of COVID-19 symptoms.

New study reinforces the importance of early detection and vaccination against bacterial meningitis.

Atea Pharmaceuticals announced topline data from their phase 2 trial showing a higher than expected efficacy for the study.

A new study shows that, among the tridemic viruses, RSV was the leading cause of pediatric hospitalizations.

This week: Insights into the comparative analysis of COVID and non-COVID pneumonia; how myopathy, with metabolic disturbances and amyloid deposits, is discovered in persons with Long COVID who experience post-exertional malaise; and the Pfizer COVID-19 vaccine is shown to be effective in children and adolescents.

With it comes the possibility for international cooperation regarding an investigational Middle East Respiratory Syndrome (MERS) vaccine.

Patients in the integrated and standard care treatment arms reported similar SCL-10 scores indicative of psychological stress and symptom burden, both at baseline and after the completion of DAA treatment.

Investigators uncover a convergent evolution of enhanced innate immune antagonist expression associated.

The Kidney Disease: Improving Global Outcomes (KDIGO) work group has published updated guidelines in the Annals of Internal Medicine for the prevention, diagnosis, evaluation, and treatment of HCV in CKD patients.

Here are some insights into the comparative analysis of COVID and non-COVID pneumonia.

Response to direct-acting antiviral therapy was similar between patients with and without HBV coinfection, with most patients completing the planned course of treatment and achieving SVR, even in the case of HBV reactivation.

A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.

Myopathy, with metabolic disturbances and amyloid deposits, is discovered in persons with Long COVID who experience post-exertional malaise.

This week's news includes emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus; how the development of antimicrobial stewardship programs can be an effective strategy for beginning to reduce this critical timing for patients in ICUs; a look at another antibiotic being studied for a healthcare-associated infection; and an investigational vaccine against the Nipah virus begins.

Emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).

How the development of antimicrobial stewardship programs can be an effective strategy for beginning to reduce this critical timing for patients in ICUs.

A new human trial aims to prevent the fatal, zoonotic-borne disease.

Doxycycline postexposure prophylaxis (PEP) has reduced STIs among men who have sex with men, but poor adherence marred trial results with women.

A new study warns an increase in costs could lead to new infections.

Investigators examined data from the Global Burden of Disease, Injuries, and Risk Factors study 2019 to describe the global, regional, and national burden of liver cancer due to hepatitis C since 1990.

Participants given omadacycline had high fecal concentrations with a distinct microbiome profile compared to those in the vancomycin group, with study results calling attention to the importance of antibiotics’ impact on the gut microbiome.